Brind.

The FDA authorized an Expanded Access Program for ANKTIVA, the lead therapy of ImmunityBio, on July 31, 2025.

1 report, 1 independent Updated Jul 31

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA ImmunityBio

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
ImmunityBio
biotech company

Nothing else this week.

Coverage

Newest first; wire copies grouped

Jul 31Insider MonkeyImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer We recently compiled a list of 11 Best Future Stocks to Buy Now. ImmunityBio, Inc. stands eleventh on our list. ImmunityBio, I